A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer

Cancer Investigation

Volumn 15, Issue 4, 1997, Pages 311-317

  Dreicer, Robert ^a,b   Kemp, John D ^a   Stegink, Lewis D ^a   Cardillo, Thomas ^a   Davis, Charles S ^a   Forest, Paula K ^a   See, William A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLHISTIDINE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANALGESIC AGENT; CREATININE; DEFEROXAMINE; HEMOGLOBIN; HYDROXYPROLINE; PROSTATE SPECIFIC ANTIGEN; TRANSFERRIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HYDROXYPROLINE URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; IRON METABOLISM; LYMPH NODE METASTASIS; MALE; METASTASIS; NAUSEA; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; URINARY EXCRETION; VISUAL IMPAIRMENT;

EID: 0030797719     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039731     Document Type: Article

References (35)

1. Bomford A, Isaac J, Roberts S, et al: The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells. Biochem J 236:243-249, 1986.
2. Taetle R, Castagnola J, Mendelsohn J: Mechanisms of growth inhibition by antitransferrin receptor monoclonal antibodies. Cancer Res 46:1759-1763, 1986.
3. Kemp JD, Thorson JA, Stewart BC, et al: Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and IgG monoclonal antibody against the transferrin receptor. Evidence for a threshold model of iron deprivation toxicity. Cancer Res 52:4144-4148, 1992.
4. Chackal-Roy M, Niemeyer C, Moore M, et al: Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 84:43-50, 1989.
5. Rossi MC, Zetter BR: Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci USA 89:6197-6201, 1992.
6. Kovar J, Naumann PW, Stewart BC, et al: Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. Pathobiology 63:65-70, 1995.
7. Donfrancesco A, Deb G, Dominici C, et al: Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50:4929-4930, 1990.
8. Weiss PH, Klein LR: The quantitative relationship of urinary peptide hydroxyproline excretion to collagen degradation. J Clin Invest 48:1-10, 1969.
9. Mundy AR: Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker. Br J Urol 51:570-574, 1979.
10. Gielen F, Dequeker J, Drochmans A, et al: Relevance of hydroxyproline excretion to bone metastasis in breast cancer. Br J Cancer 34:279-285, 1976.
11. Ballard FJ, Tomas FM: 3-Methylhistidine as a measure of skeletal muscle-protein breakdown in human subjects: The case for its continued use. Clin Sci 65:209-215, 1983.
12. Hallaway PE, Eaton JW, Panier SS, et al: Modulation of deferoxamine toxicity and clearance by covalent attachment to biocampatible polymers. Proc Natl Acad Sci USA 86:10108-10112, 1989.
13. Lipton WE, Li Y-N, Younoszai MK, et al: Intestinal absorption of aspartame decomposition products in adult rats. Metabolism 40:1337-1345, 1991.
14. O'Brien D, Ibbot FA, Rodgerson DO: Laboratory Manual of Pediatric Microbiochemical Techniques, 4th ed. New York, Harper & Row, 1968, pp 114-116.
15. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989.
16. Melzack R: The McGill Pain Questionnaire: Major properties and scoring methods. Pain 2:277-299, 1975.
17. Selby PJ, Chapman JAW, Etazadi-Amoli J, et al: The development of a method for assessing the quality of life of cancer patients. Br J Cancer 50:13-22, 1984.
18. Hudes GR, Greenberg R, Krigel RL, et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992.
19. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994.
20. Roth B: Combination chemotherapy in advanced prostate cancer: A silk purse? J Clin Oncol 12:2001-2002, 1994.
21. Myers C, Cooper M, Stein C, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992.
22. Eisenberger MA, Reyno LM, Jodrell DI, et al: Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J Natl Cancer Inst 85:611-621, 1993.
23. Heidenberg HB, Sesterhenn IA, Gaddipati JP, et al: Alteration of the tumor suppressor gene P53 in a high fraction of hormone refractory prostate cancer. J Urol 154:414, 1995.
24. Hamdy FC, Thurrell W, Lawry J, et al: p53 mutant expression correlates with hormone sensitivity and prognosis in human prostatic adenocarcinoma. J Urol 149 (part 2):377A, 1993 (abstract 658).
25. Theyer G, Schirmböck M, Thalhammer T: Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 150:1544-1547, 1993.
26. Hann HL, Stahlhut MW, Blumberg BS: Iron nutrition and tumor growth: Decreased tumor growth in iron deficient mice. Cancer Res 48:4168-4170, 1988.
27. Bergeron RJ, Streiff RR, Elliot GT: Influence of iron on in vivo proliferation and lethality of L1210 cells. J Nutr 115:369-374, 1985.
28. Kondo K, Noguchi M, Mukai K, et al: Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest 97:1367-1371, 1990.
29. Faulk WP, Hsi BL, Stevens PJ: Transferrin and transferrin receptors in carcinoma of the breast. Lancet 2:390-392, 1980.
30. Keer HN, Kozlowski JM, Tsai YC, et al: Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol 143:381-385, 1990.
31. Foa P, Maiolo AT, Lombardi L, et al: Inhibition of proliferation of human leukaemic cell populations by desferrioxamine. Scand J Haematol 36:107-110, 1986.
32. Becton DL, Bryles P: Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 48:7189-7192, 1988.
33. Summers MR, Jacobs A, Tudway D, et al: Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42:547-555, 1979.
34. Voest EE, Rooth H, Neijt JP, et al: The in vitro response of human tumor cells to desferrioxamine is growth medium dependent. Cell Prolif 26:77-88, 1993.
35. Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993.